Valuation: Alterity Therapeutics Limited

Market Cap 89.82M 78.51M 72.61M 66.62M 126M 8.65B 128M 866M 340M 4.23B 337M 330M 14.59B P/E 2026 *
-0.35x
P/E 2027 * -0.34x
Enterprise Value 44.63M 39.01M 36.08M 33.1M 62.65M 4.3B 63.74M 430M 169M 2.1B 168M 164M 7.25B EV / Sales 2026 *
17.4x
EV / Sales 2027 * 40.8x
Free-Float
91.76%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Alterity Therapeutics Limited

1 day+450.00%
6 months-89.81%
Current year-82.40%
1 week 0
Extreme 0.0011
0.45
1 month 0
Extreme 0.0011
0.45
Current year 0
Extreme 0.0011
0.54
1 year 0
Extreme 0.0011
0.54
3 years 0
Extreme 0.0011
0.7
5 years 0
Extreme 0.0011
2.36
10 years 0
Extreme 0.0011
4.75
Manager TitleAgeSince
Chief Executive Officer 65 06/01/2021
Director of Finance/CFO - 29/09/2024
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 70 28/07/2005
Director/Board Member 47 07/08/2011
Director/Board Member 65 20/11/2025
Change 5-day change 1-year change 3-year change Capi.($)
+450.00%-.--% - - 87.53M
-1.07%-1.27%+0.95%+6.28% 50.35B
-3.49%-6.87%+363.54%+568.92% 39.21B
+2.33%+0.54%+32.44%-5.09% 34.52B
+2.17%+4.92%+13.82%+60.55% 34.6B
+0.06%-0.57%+3.35%+27.42% 27.05B
-1.65%-4.65% - - 16.68B
+1.99%+0.64%+71.17%+117.86% 15.11B
+0.29%+1.02%+14.95%+18.32% 13.85B
-0.46%+1.26%+18.65%-30.26% 13.18B
Average +44.97%+0.81%+64.86%+95.50% 27.17B
Weighted average by Cap. -0.07%+0.70%+76.88%+118.14%

Financials

2026 *2027 *
Net sales 2.57M 2.25M 2.08M 1.91M 3.61M 247M 3.67M 24.76M 9.73M 121M 9.65M 9.43M 417M 1.2M 1.05M 970K 890K 1.69M 116M 1.71M 11.57M 4.55M 56.48M 4.51M 4.41M 195M
Net income -14.64M -12.8M -11.84M -10.86M -20.56M -1.41B -20.92M -141M -55.46M -689M -54.99M -53.78M -2.38B -29.66M -25.93M -23.98M -22M -41.64M -2.86B -42.36M -286M -112M -1.4B -111M -109M -4.82B
Net Debt -45.19M -39.5M -36.53M -33.52M -63.44M -4.35B -64.54M -436M -171M -2.13B -170M -166M -7.34B -40.88M -35.73M -33.05M -30.33M -57.39M -3.94B -58.39M -394M -155M -1.92B -154M -150M -6.64B
Logo Alterity Therapeutics Limited
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. Its lead asset, ATH434, is in a randomized, double blind, placebo-controlled Phase II clinical trial in participants with MSA. The Company is also conducting various nonclinical studies with ATH434 for use in Parkinson’s disease based on imaging of brain iron, preservation of neurons, and improvements in motor performance.
Employees
9
Date Price Change Volume
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.5900AUD
Average target price
2.280AUD
Spread / Average Target
+286.44%

Quarterly revenue - Rate of surprise